Overview of the RGD-Based PET Agents Use in Patients With Cardiovascular Diseases: A Systematic Review

Dietz, Matthieu; Kamani, Christel H.; Dunet, Vincent; Fournier, Stéphane; Rubimbura, Vladimir; Dardel, Nathalie Testart; Schaefer, Ana; Jreige, Mario; Boughdad, Sarah; Lalonde, Marie Nicod; Schaefer, Niklaus; Mewton, Nathan; Prior, John O.; Treglia, Giorgio

doi:10.3389/fmed.2022.887508

Cited by 6 publications

(16 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By comparing 18 F-FPPRGD 2 and 18 F-FDG uptake values in various non-esophageal cancer patients, those authors showed no significant difference in tumor-to-background ratios between both tracers. The low RGD-based tracer uptake in several areas such as the lung, muscles, fat, the brain, or the myocardium could be an advantage for both qualitative and quantitative evaluation of thoracic, breast or brain lesions (Beer et al 2008 ; Minamimoto et al 2015 ), or for non-oncological applications such as cardiovascular imaging or inflammatory diseases (Dietz et al 2021 , 2022 ; Ebenhan et al 2021 ; Zhu et al 2014 ).…”

Section: Discussionmentioning

confidence: 99%

“…Arginine-glycine-aspartate (RGD) peptides have a high binding affinity and specificity with integrin α v β 3 . As a result, a variety of RGD-based positron emission tomography (PET) imaging agents have been developed to visualize integrin α v β 3 expression (Chen et al 2016 ; Dietz et al 2022 ). NODAGA-RGDyK, (cyclo[L-arginylglycyl-L-alpha-aspartyl-D-tyrosyl-N6-([4,7-bis(carboxymethyl)octahydro-1H-1,4,7-triazonin-1-yl]acetyl])-L-lysyl]), is a recently developed RGD peptide designed for PET imaging of α v β 3 integrin expression (Jeong et al 2008 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of integrin αvβ3 expression with 68Ga-NODAGA-RGD PET/CT and glucose metabolism with 18F-FDG PET/CT in esophageal or gastroesophageal junction cancers

Dietz

Dunet

Mantziari

et al. 2023

European J Hybrid Imaging

Self Cite

View full text Add to dashboard Cite

Background The primary aims of this study were to compare in patients with esophageal or esophagogastric junction cancers the potential of 68Ga-NODAGA-RGD PET/CT with that of 18F-FDG PET/CT regarding tumoral uptake and distribution, as well as histopathologic examination. Methods Ten 68Ga-NODAGA-RGD and ten 18F-FDG PET/CT were performed in nine prospectively included participants (1 woman; aged 58 ± 8.4 y, range 40–69 y). Maximum SUV (SUVmax) and metabolic tumor volumes (MTV) were calculated. The Mann–Whitney U test and Spearman correlation analysis (ρ) were used. Results 68Ga-NODAGA-RGD PET/CT detected positive uptake in 10 primary sites (8 for primary tumors and 2 for local relapse suspicion), 6 lymph nodes and 3 skeletal sites. 18F-FDG PET/CT detected positive uptake in the same sites but also in 16 additional lymph nodes and 1 adrenal gland. On a lesion-based analysis, SUVmax of 18F-FDG was significantly higher than those of 68Ga-NODAGA-RGD (4.9 [3.7–11.3] vs. 3.2 [2.6–4.2] g/mL, p = 0.014). Only one participant showed a higher SUVmax in an osseous metastasis with 68Ga-NODAGA-RGD as compared to 18F-FDG (6.6 vs. 3.9 g/mL). Correlation analysis showed positive correlation between 18F-FDG and 68Ga-NODAGA-RGD PET parameters (ρ = 0.56, p = 0.012 for SUVmax, ρ = 0.78, p < 0.001 for lesion-to-background ratios and ρ = 0.58, p = 0.024 for MTV). We observed that 18F-FDG uptake was homogenous inside all the confirmed primary sites (n = 9). In contrast, 68Ga-NODAGA-RGD PET showed more heterogenous uptake in 6 out of the 9 confirmed primary sites (67%), seen mostly in the periphery of the tumor in 5 out of the 9 confirmed primary sites (56%), and showed slight extensions into perilesional structures in 5 out of the 9 confirmed primary sites (56%). Conclusions In conclusion, 68Ga-NODAGA-RGD has lower potential in the detection of esophageal or esophagogastric junction malignancies compared to 18F-FDG. However, the results suggest that PET imaging of integrin αvβ3 expression may provide complementary information and could aid in tumor diversity and delineation. Trial registration: Trial registration: NCT02666547. Registered January 28, 2016—Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT02666547.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Comparison of integrin αvβ3 expression with 68Ga-NODAGA-RGD PET/CT and glucose metabolism with 18F-FDG PET/CT in esophageal or gastroesophageal junction cancers

Dietz

Dunet

Mantziari

et al. 2023

European J Hybrid Imaging

Self Cite

View full text Add to dashboard Cite

show abstract

“…The development of novel PET tracers is an active area of extensive research. Some of these novel tracers, including 18F-FMISO, 68Ga-NOTA-RGD, and 18F-NAF, are being studied in humans as alternative markers of inflammation and potential markers for microcalcification, respectively, with some success [ 175 , 183 , 184 ]. Furthermore, 18F-NAF specifically targets active microcalcification in atherosclerotic plaques, which could be valuable in identifying vulnerable carotid plaques.…”

Section: Biomarkers Of Non-invasive Imagingmentioning

confidence: 99%

Novel Imaging-Based Biomarkers for Identifying Carotid Plaque Vulnerability

et al. 2023

View full text Add to dashboard Cite

Carotid artery disease has traditionally been assessed based on the degree of luminal narrowing. However, this approach, which solely relies on carotid stenosis, is currently being questioned with regard to modern risk stratification approaches. Recent guidelines have introduced the concept of the “vulnerable plaque,” emphasizing specific features such as thin fibrous caps, large lipid cores, intraplaque hemorrhage, plaque rupture, macrophage infiltration, and neovascularization. In this context, imaging-based biomarkers have emerged as valuable tools for identifying higher-risk patients. Non-invasive imaging modalities and intravascular techniques, including ultrasound, computed tomography, magnetic resonance imaging, intravascular ultrasound, optical coherence tomography, and near-infrared spectroscopy, have played pivotal roles in characterizing and detecting unstable carotid plaques. The aim of this review is to provide an overview of the evolving understanding of carotid artery disease and highlight the significance of imaging techniques in assessing plaque vulnerability and informing clinical decision-making.

show abstract

“…Developing novel PET tracers is an active area of in-depth research. These novel tracers include 18 F-FMISO, 68 GA-NOTA-RGD, and 18 F-NAF ( 38 , 39 ). 18 F-NAF, in particular, is a tracer for active microcalcification in atherosclerotic plaques, which could be useful in identifying vulnerable carotid plaques.…”

Section: Imaging Identification Of Vulnerable Carotid Plaquementioning

confidence: 99%

Detecting vulnerable carotid plaque and its component characteristics: Progress in related imaging techniques

et al. 2022

View full text Add to dashboard Cite

Carotid atherosclerotic plaque rupture and thrombosis are independent risk factors for acute ischemic cerebrovascular disease. Timely identification of vulnerable plaque can help prevent stroke and provide evidence for clinical treatment. Advanced invasive and non-invasive imaging modalities such as computed tomography, magnetic resonance imaging, intravascular ultrasound, optical coherence tomography, and near-infrared spectroscopy can be employed to image and classify carotid atherosclerotic plaques to provide clinically relevant predictors used for patient risk stratification. This study compares existing clinical imaging methods, and the advantages and limitations of different imaging techniques for identifying vulnerable carotid plaque are reviewed to effectively prevent and treat cerebrovascular diseases.

show abstract

Overview of the RGD-Based PET Agents Use in Patients With Cardiovascular Diseases: A Systematic Review

Cited by 6 publications

References 46 publications

Comparison of integrin αvβ3 expression with 68Ga-NODAGA-RGD PET/CT and glucose metabolism with 18F-FDG PET/CT in esophageal or gastroesophageal junction cancers

Comparison of integrin αvβ3 expression with 68Ga-NODAGA-RGD PET/CT and glucose metabolism with 18F-FDG PET/CT in esophageal or gastroesophageal junction cancers

Novel Imaging-Based Biomarkers for Identifying Carotid Plaque Vulnerability

Detecting vulnerable carotid plaque and its component characteristics: Progress in related imaging techniques

Contact Info

Product

Resources

About